A self administered reliable questionnaire to assess lower bowel symptoms

Abstract

BackgroundBowel symptoms are considered indicators of the presence of colorectal cancer and other bowel diseases. Self administered questionnaires that elicit information about lower bowel symptoms have not been assessed for reliability, although this has been done for upper bowel symptoms. Our aim was to develop a self administered questionnaire for eliciting the presence, nature and severity of lower bowel symptoms potentially related to colorectal cancer, and assess its reliability.MethodsImmediately before consulting a gastroenterologist or colorectal surgeon, 263 patients likely to have a colonoscopy completed the questionnaire. Reliability was assessed in two ways: by assessing agreement between patient responses and (a) responses given by the doctor at the consultation; and (b) responses given by patients two weeks later.ResultsThere was more than 75% agreement for 78% of the questions for the patient-doctor comparison and for 92% of the questions for the patient-patient comparison. Agreement for the length of time a symptom was present, its severity, duration, frequency of occurrence and whether or not medical consultation had been sought, all had agreement of greater than 70%. Over all questions, the chance corrected agreement for the patient-doctor comparison had a median kappa of 65% (which represents substantial agreement), interquartile range 57–72%. The patient-patient comparison also showed substantial agreement with a median kappa of 75%, interquartile range 68–81%.ConclusionThis self administered questionnaire about lower bowel symptoms is a useful way of eliciting details of bowel symptoms. It is a reliable instrument that is acceptable to patients and easily completed. Its use could guide the clinical consultation, allowing a more efficient, comprehensive and useful interaction, ensuring that all symptoms are assessed. It will also be a useful tool in research studies on bowel symptoms and their predictive value for colorectal cancer and other diseases. Studies assessing whether bowel symptoms predict the presence of colorectal cancer should provide estimates of the reliability of the symptom elicitation.

Frequency of Chronic Gastrointestinal Distress in Runners: Validity and Reliability of a Retrospective Questionnaire

“…In regards to reliability properties, the Spearman's rho correlations from Table 3 suggest the retrospective questionnaire was moderately-to-highly reliable (all rho ≥ 0.78) for measurements taken no more than seven days apart. The favorable reliability observed in this sample of runners reaffirms other research that has found retrospective GI symptom reports to have acceptable test-retest reliability in nonathletes (Adelstein et al, 2008). Taking the validity and reliability evaluations together, this investigation provides reassurance for investigators wishing to use retrospective questionnaires as a convenient way to measure chronic GI symptomology in endurance runners.…”

The value of age and medical history for predicting colorectal cancer and adenomas in people referred for colonoscopy

“…Information about symptoms was also consistently collected using a validated questionnaire [16]. A further strength of our study is that it represents a heterogeneous population which reflects what occurs in clinical practice in the real world and allows exploration of what factors that make up that heterogeneity predict the probability of cancer or adenomas.…”

Self-reported endocrine late effects in adults treated for brain tumours, Hodgkin and non-Hodgkin lymphoma: a registry based study in Northern Germany

“…Moreover, our observations are derived from questionnaire-based voluntary selfdisclosures and not the actual medical records, which may distort our information on concurrent diseases and introduce inaccuracy regarding medical treatment. However, other health-care studies have shown that patients can provide valid (55) and reliable (56,57,58) information about their treatment and diseases. Furthermore, the epidemiological cancer registry only collected data concerning first line therapy following initial diagnosis.…”